contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nextcell-pharma-ab-nextcell-pharma-publishes-annual-report-20242024

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

NextCell Pharma operates in the healthcare sector. The company develops stem cell products that are mainly used in the treatment of autoimmune diabetes and kidney transplantation. A large part of the work consists of stem cell research where the company develops drug candidates that will facilitate and increase acceptance in organ transplantation. In addition, the company owns a stem cell bank. The company was founded in 2014 and has its headquarters in Huddinge.

Today, NextCell released information regarding a collaboration with Fujifilm Biosciences. They are launching their first joint commercial product for research use. Fujifilm, a multi-billion dollar company, is a global leader in the development of cell culture materials. NextCell’s patented expertise using an MSC (Mesenchymal Stem Cell) selection algorithm—which produced the Phase 2 candidate ProTrans—is likely part of this collaboration. The commercial product is NextCell-Cord RUO, which consists of selected MSCs in cell culture media as various products. These are intended for research use only (RUO). Fujifilm will handle the global marketing. In the short term, over a one-year horizon, the financial impact of this activity on NextCell’s results is estimated to be limited. The point, however, is that cell research and therapy volume is a growing field. I recently saw an estimate that the annual revenue growth for service operations in this sector could be around 30% per year. As previously noted in this thread, NextCell’s cell business at these current market valuations leaves something for the shareholders, even if ProTrans were to “do a Diamyd” (fail in late-stage trials).

Trading volume has picked up today, and about 3 million shares have already been traded in an hour. The stock is now at that one krona mark; it’s easy to guess that Diamyd has finalized its next steps and is now selling off its holdings. According to AI, they had about 5 million shares. So today, it dropped 15% right at the start of trading to that one krona level, and there is no news for today. I bought some now, assuming that the threat of Diamyd’s selling pressure is dissipating, and I believe they have also figured out in advance at what price the position could be offloaded—i.e., at what price a large buyer/buyers can be found.

Diamyd apparently owns about 15% of NextCell. Diamyd plummeted 90% today, and now there’s likely concern they’ll dump their NextCell shares due to a cash crunch. NextCell has dropped about 15% today. What are your thoughts on the situation? Is there also a slight worry creeping in about the viability of NextCell’s development pipeline?

Diabettech - Diabetes and Technology | Where Diabetes and Technology meet – 3 Mar 26              100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure...    Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But...

Results are out.  The report is still messy and incomplete. CEO comments are conspicuous by their absence, etc. This started in the previous quarterly report after the CFO left. Apparently, the new CFO has not fixed the issue. The report covers an exceptional 16-month financial year (September 2024 → December 2025) due to a change in the fiscal year, which makes direct comparison to previous years difficult. The company has admitted to this confusion and announced it will publish a separate comparison document to clarify the figures shortly after the report. Revenue from QVance does not yet appear to be recognized, which is a disappointment. This is in direct contradiction with the company’s comments that turnover would have accumulated since at least late summer. In practice, however, it seems that QVance’s sales are visible in the items Advances received and commitments (+1.1 MSEK, the parent company’s share of this growth was almost non-existent), Unbilled work and accrued income (increased by approx. 0.9 MSEK from a year ago), and Accounts receivable (increased by approx. 1M SEK at the point when QVance was said to have become operational). Although accounts receivable and advances point to some kind of operational activity, the company’s cash position fell to 26 million kronor by the end of 2025 (32.7 MSEK the previous year). This was influenced at least by QVance’s new isolator, which appears on the balance sheet likely as a 4.4 million kronor work-in-progress acquisition.             cdn.prod.website-files.com              699fe987c9e393af67bc206d_NextCell%20Bokslutskommunik%C3%A9%202024%202025%20SV.pdf    643.52 KB                            Edit: The CEO will comment on the quarter tonight: Digital temakväll - Life Science | Aktiespararna

The company is truly an extreme example of poor liquidity for a listed company. Last Friday at the open: 10:03 share 1.68 (+7%) 10:05 share 1.51 (-4%) Today the range was even wider. At the open, it rose +9.5%, and a couple of minutes later, it dipped to -5.5%. Hardly any trades were made; rather, this was most likely just the momentary spread of the share. Interested by this, I tried to figure out how large the actual float of the share is, assuming we count all “sticky money” (tahmainen raha)—meaning, in addition to insiders, long-term anchor investors, larger institutions, partners, etc. Instead of calculating it myself, I fed Gemini the insider transactions, key press releases, and the latest samples of the top 10 shareholders and debated for a while, correcting errors. Getting an exact figure is difficult because part of this rigid ownership is in nominee registers, and insider ownership is also held through separate holding/investment companies. Overall, it could be said that at least a good third (over 36%) of the company is somewhat “cemented,” meaning likely not active on the market (even though there are no legal barriers to selling). Optimistically, sticky money could amount to as much as 60 million shares, or about half, if we make a rough order-of-magnitude estimate of long-term investors from previous offerings. Whatever the “effective free float” is, it can generally be assumed to have decreased following the '25 subscription and the '26 direct investment, explaining the increased volatility to some extent. Additionally, a significant portion of retail investors’ NextCell positions are surely at the bottom of portfolios, 70%–90% in the red, and there is no interest in realizing those losses. The company’s record 1-month volume, which has only been broken in terms of share count by the recent Hong Kong news and the 2025 Pro-Young results announcement + rights issue, was set in September 2020 at a price over 10 times higher than the current one. In terms of euro value, those recent volumes fall far behind. Earnings release coming up on Thursday!

New press release and the stock is showing new momentum, up 12% today. For the sharp-eyed, however, this isn’t new information, because even though Nextcell hasn’t communicated this directly to investors, yours truly spotted this 29 days ago in this discussion.

NextCell Pharma

NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Annual Report for the extended financial year September 1, 2024 - December 31, 2025. The Annual Report is available in Swedish...

<div class="abstract"><p><span><span><span><span><span>NextCell&nbsp;Pharma AB (publ) ("NextCell" or the "Company")&nbsp;publishes its&nbsp;Annual Report for the&nbsp;extended&nbsp;financial year&nbsp;September 1, 2024 - December 31, 2025.&nbsp;The Annual Report is available in Swedish as an appendix to this press release or on the company's website: www.nextcellpharma.com. NextCells&nbsp;share is traded on Nasdaq First North Growth Market under the ticker "NXTCL".&nbsp;</span></span></span></span></span></p></div><p>&nbsp; &nbsp;&nbsp;</p><div></div>